dc.contributor.author | Schifano, Fabrizio | |
dc.contributor.author | Oyefeso, A. | |
dc.contributor.author | Corkery, John | |
dc.contributor.author | Cobain, K. | |
dc.contributor.author | Jambert-Gray, R. | |
dc.contributor.author | Martinotti, G. | |
dc.contributor.author | Ghodse, A. Hamid | |
dc.date.accessioned | 2011-08-15T10:01:02Z | |
dc.date.available | 2011-08-15T10:01:02Z | |
dc.date.issued | 2003 | |
dc.identifier.citation | Schifano , F , Oyefeso , A , Corkery , J , Cobain , K , Jambert-Gray , R , Martinotti , G & Ghodse , A H 2003 , ' Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002 ' , Human Psychopharmacology: Clinical and Experimental , vol. 18 , no. 7 , pp. 519-524 . https://doi.org/10.1002/hup.528 | |
dc.identifier.issn | 0885-6222 | |
dc.identifier.uri | http://hdl.handle.net/2299/6168 | |
dc.description | The full text of this article is not available in the UHRA | |
dc.description.abstract | The present study reports on all deaths related to taking ecstasy (alone, or in a polydrug combination) occurring in England and Wales in the time frame August 1996-April 2002. Data presented here are based on all information recorded in the National Programme on Substance Abuse Deaths (np-SAD) database. The np-SAD regularly receives all information on drug related deaths in addicts and non addicts from coroners. A total of 202 ecstasy-related fatalities occurred in the chosen time-frame, showing a steady increase in the number of deaths each year. The ratio male:female was 4:1 and 3 of 4 victims were younger than 29. In 17% of cases ecstasy was the sole drug implicated in death and in the remaining cases a number of other drugs (mostly alcohol, cocaine, amphetamines and opiates) have been found. According to toxicology results, MDMA accounted for 86% of cases and MDA for 13% of cases; single deaths were associated with MDEA and PMA. This is the largest sample of ecstasy related deaths so far; possible explanations are given for the observed steady increase in ecstasy-related deaths and a tentative 'rationale' for this polypharmacy combination is then proposed. Copyright (C) 2003 John Wiley Sons, Ltd. | en |
dc.format.extent | 6 | |
dc.language.iso | eng | |
dc.relation.ispartof | Human Psychopharmacology: Clinical and Experimental | |
dc.subject | 3,4-Methylenedioxyamphetamine | |
dc.subject | Adolescent | |
dc.subject | Adult | |
dc.subject | Amphetamine-Related Disorders | |
dc.subject | Benzodiazepines | |
dc.subject | Cannabinoids | |
dc.subject | Cocaine | |
dc.subject | Drug Interactions | |
dc.subject | England | |
dc.subject | Ethanol | |
dc.subject | Female | |
dc.subject | Hallucinogens | |
dc.subject | Heroin | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | N-Methyl-3,4-methylenedioxyamphetamine | |
dc.subject | Wales | |
dc.title | Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002 | en |
dc.contributor.institution | School of Life and Medical Sciences | |
dc.contributor.institution | Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit | |
dc.contributor.institution | Department of Clinical, Pharmaceutical and Biological Science | |
dc.contributor.institution | Centre for Health Services and Clinical Research | |
dc.description.status | Peer reviewed | |
rioxxterms.versionofrecord | 10.1002/hup.528 | |
rioxxterms.type | Journal Article/Review | |
herts.preservation.rarelyaccessed | true | |